Literature DB >> 12954211

The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4(+) T cell loss caused by the simian-human immunodeficiency virus SHIV(KU-lbMC33) in pig-tailed macaques.

Dinesh K Singh1, Darcy M Griffin, Erik Pacyniak, Mollie Jackson, Michael J Werle, Bo Wisdom, Francis Sun, David R Hout, David M Pinson, Robert S Gunderson, Michael F Powers, Scott W Wong, Edward B Stephens.   

Abstract

The simian-human immunodeficiency virus (SHIV)/ macaque model for human immunodeficiency virus type 1 has become a useful tool to assess the role of Vpu in lentivirus pathogenesis. In this report, we have mutated the two phosphorylated serine residues of the HIV-1 Vpu to glycine residues and have reconstructed a SHIV expressing this nonphosphorylated Vpu (SHIV(S52,56G)). Expression studies revealed that this protein was localized to the same intracellular compartment as wild-type Vpu. To determine if this virus was pathogenic, four pig-tailed macaques were inoculated with SHIV(S52,56G) and virus burdens and circulating CD4(+) T cells monitored up to 1 year. Our results indicate that SHIV(S52,56G) caused rapid loss in the circulating CD4(+) T cells within 3 weeks of inoculation in one macaque (CC8X), while the other three macaques developed no or gradual numbers of CD4(+) T cells and a wasting syndrome. Histological examination of tissues revealed that macaque CC8X had lesions in lymphoid tissues (spleen, lymph nodes, and thymus) that were typical for macaques inoculated with pathogenic parental SHIV(KU-1bMC33) and had no lesions within the CNS. To rule out that macaque CC8X had selected for a virus in which there was reversion of the glycine residues at positions 52 and 56 to serine residues and/or compensating mutations occurred in other genes associated with CD4 down-regulation, sequence analysis was performed on amplified vpu sequences isolated from PBMC and from several lymphoid tissues at necropsy. Sequence analysis revealed a reversion of the glycine residues back to serine residues in this macaque. The other macaques maintained low virus burdens, with one macaque (P003) developing a wasting syndrome between months 9 and 11. Histological examination of tissues from this macaque revealed a thymus with severe atrophy that was similar to that of a previously reported macaque inoculated with a SHIV lacking vpu (Virology 293, 2002, 252). Sequence analysis revealed no reversion of the glycine residues in the vpu sequences isolated from this macaque. These results contrast with those from four macaques inoculated with the parental pathogenic SHIV(KU-1bMC33), all of which developed severe CD4(+) T cell loss within 1 month after inoculation. Taken together, these results indicate that casein kinase II phosphorylation sites of Vpu contributes to the pathogenicity of the SHIV(KU-1bMC33) and suggest that the SHIV(KU-1bMC33)/pig-tailed macaque model will be useful in analyzing amino acids/domains of Vpu that contribute to the pathogenesis of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954211     DOI: 10.1016/s0042-6822(03)00339-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

2.  Comparison of the replication and persistence of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA or HCCH domains in macaques.

Authors:  Kimberly Schmitt; M Sarah Hill; Zhenqian Liu; Autumn Ruiz; Nathan Culley; David M Pinson; Edward B Stephens
Journal:  Virology       Date:  2010-09-01       Impact factor: 3.616

3.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

4.  BST-2 mediated restriction of simian-human immunodeficiency virus.

Authors:  Autumn Ruiz; David Lau; Richard S Mitchell; M Sarah Hill; Kimberly Schmitt; John C Guatelli; Edward B Stephens
Journal:  Virology       Date:  2010-08-13       Impact factor: 3.616

5.  Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

6.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

7.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

8.  Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.

Authors:  M Sarah Hill; Autumn Ruiz; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

9.  Simian-Human immunodeficiency viruses expressing chimeric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmembrane domains in the rate of CD4(+) T cell loss in macaques.

Authors:  Autumn Ruiz; Kimberly Schmitt; Nathan Culley; Edward B Stephens
Journal:  Virology       Date:  2012-12-05       Impact factor: 3.616

10.  Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; John Guatelli; Edward B Stephens
Journal:  Virology       Date:  2008-06-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.